US stocks pulled back on Tuesday, led by a nearly 2% decline in the Nasdaq, following two days of gains as investors ...

Amezosvatein has shown excellent immunogenicity and improved tolerability in Phase 2 study -- Medicxi leads round, joined by new investors ...

The kickoff of Nvidia's biggest conference of the year — the annual GTC event — was in the spotlight, as investors awaited the debut of the company's Blackwell Ultra AI chip a ...

we can see how our therapeutics work in different populations, helping us to advance our pipeline to meet unmet needs in patients worldwide,” said Xueming Qian, founder, chair and CEO of Transcenta.

IBT is expertly designed and staffed with a collective 150+ years of experience in early-stage research supporting therapeutics and ... Michael Wilhelm, CEO of LNS, stated: “We are excited ...

US stocks (^DJI, ^IXIC, ^GSPC) capped off Tuesday's session in negative territory, snapping the last two trading days' worth ...

Philadelphia—Brent Pfeiffenberger, the President and CEO of Century Therapeutics , Inc. (NASDAQ:IPSC), recently sold 34,712 shares of the company's common stock. The shares were sold at an ...

Brent Pfeiffenberger, President and CEO of Century Therapeutics , Inc. (NASDAQ:IPSC), recently executed a transaction involving the sale of 2,235 shares of the company’s common stock. The shares were ...

Amicus Therapeutics has two products in the market ... 2025 and the years ahead," said Bradley Campbell, the company’s CEO, in an investor call Wednesday morning. “We have firmly established ...